Resume

Sign in

Medical Human

Location:
Wallingford, Pennsylvania, 19086, United States
Posted:
March 28, 2011

Contact this candidate
Sponsored by:
TalentDesk
Post Jobs to
Multiple Job Boards &
Get more Candidates
Try it Free!
Start your 30-day
Free Trial

Dr. Sharad P. Adekar M.D.

**** ****** ****

Wallingford, PA 19086

abhnn7@r.postjobfree.com

Work Authorization Status: Permanent Resident of USA

Work Address: Immunome, Inc

Lankenau Institute for Medical Research

Room No 227

100 E Lancaster Ave,

Wynnewood, PA-19096

Ph no. 484-***-****

Email: abhnn7@r.postjobfree.com

Summary

I have over 7 yrs of experience in human hetero-hybriodom development where

I have created most efficient method to generate human monoclonal

antibodies. I have used this method for generation of human monoclonal

antibodies against vaccinia virus, rabies virus, influenza virus, botulinum

neuro-toxin, clostridium difficile toxin and amyloid peptides.

Professional experience

Immunome Inc September 2008- Present

Wynnewood, PA

Director of Antibody Research

Responsible for efficient management of R&D projects via interaction with

team members.

Essential Duties and Responsibilities

. Manage the R&D group by monitoring the progress of the projects closely

on a day-today basis

. Provide scientific oversight for the activities of the R&D group; assist

the team leaders in developing R&D plans and experimental designs for all

projects

. Work on independent R&D projects to develop new antibodies

. Ensure that accurate and technically rich data sheets/protocols for all

new antibodies are written in a timely manner

. Keep in touch with the latest, cutting edge scientific research through

reading the literature and/or attending scientific meetings, seminars, etc.

. Coordinate regular R&D meetings to discuss the progress of all current

R&D projects and get feedback from other members

Key achievements in one year

Human monoclonal antibodies against clostridium difficile toxin

Designed, developed and running project on cloning of human monoclonal

antibodies against clostridium difficile toxin.

Developed cell-based assays for testing biological activity of these

antibodies.

Completed testing of neutralization activity of antibodies in mice.

Made large scale production of antibodies for Hamster studies.

Lankenau Institute for Medical Research November 2007-

Present

Wynnewood, PA

Scientist

Key achievements

Human monoclonal antibodies against Botulinum toxin

. Designed, Developed and characterized more than 20 human

monoclonal antibodies neutralizing bioterror agent

botulinum neuro-toxin.

. Antibodies have pico-molar affinity tested by kinetic

exclusion assay (KinExa).

. With these antibodies, developed ultra-sensitive assay for

detection of botulinum toxin in blood and milk samples.

Human monoclonal antibodies against abeta-peptide (Alzheimer's

disease)

. Designed, Developed and characterized around 10 human

monoclonal antibodies that bind to abeta-peptide and JTO-

light chain in Alzheimer's disease.

. Developed heavy chain only human monoclonal antibodies that

inhibit abeta-fibrils initiation and elongation.

. These antibodies bind to abeta-peptide plaques in

Alzheimer's disease brains.

Human monoclonal antibodies against Rabies virus

. Designed and developed 6 human monoclonal antibodies

against rabies virus.

Human monoclonal antibodies against Influenza virus

. Designed, Developed and characterized 4 human monoclonal

antibodies against influenza virus.

Cardeza Foundation For Hematologic Research March 2003- November 2007

Thomas Jefferson University, Philadelphia, PA

Post-doctoral Fellow

Human hybridoma technology development

. Developed a novel three step-hybridoma method that

efficiently overcomes limitations of old traditional

hybridoma method. Peripheral blood mononuclear cells

(PBMCs) are (1) selected for expression of CD27, a marker

of B-cells that express affinity-matured antibodies, (2)

cultured in vitro to promote B-cell proliferation and class-

switching, and (3) fused to a genetically modified myeloma

cell line that efficiently produces stable hybridoma cells

secreting human monoclonal antibodies.

. Created a novel fusion partner cell line that express human

telomerase (hTERT) and mouse interleukin-6 (mIL-6).

Human monoclonal antibodies against botulinum toxin

. Designed and developed project to generate human monoclonal

antibodies against botulinum toxin.

Interactive Research School For Health Affairs August 2001- March 2003

Bharti Vidyapeeth Medical College, Pune, India

Scientist and Attending Physician

. Developed a project to see role of omega-3 fatty acids in

pregnancy-induced hypertension

Education

1991-1996 M.B.B.S. B.J. Medical College, Pune, India.

1996-1997 Medical Internship. Cantonment Hospital, Pune & Primary Health

Centre, Nasarapur, India.

1997-1998 Medical Officer. Primary Health Centre, Palasdev, Indapur,

India.

1998-2001 M.D. B.J. Medical College, Pune, India.

Academic Honors

1989 S.S.C.- 17th in the merit list of Pune Board.

1991 H.S.C.- 20th in the merit list of Pune Board.

1991 National Merit Scholarship holder in Medical College.

2001 First in Pune University between M.D. and M.S.

Candidates of all different branches.

Current grant support

1R43AI079999-01 (Adekar Sharad, PI) Jan 2009-2010

A heteropolymer antibody for treatment of serotype B BoNT

NIH study section

2008 october Temporary member, study section: ZAI1 AR-M (C2)

Application of Platform Technologies for the Development of

Therapeutics for Biodefense.

Guest Lectures

Feb 2001 Poona chapter of Obstetrics & Gynecology Association

Topic: Role of Omega-3 fatty acids in Pregnancy-induced

Hypertension

Board Certification

Medical Council of India, Medicine, 1997

Medical Biochemistry, 2001

Membership

American society of microbiology

Publication

Adekar SP, Klyubin I, Macy S, Rowan MJ, Solomon A, Dessain SK, O'Nuallain

B. Inherent anti-amyloidogenic activity of human Ig {gamma} heavy chains. J

Biol Chem. 2009 Nov 4. [Epub ahead of print]

Adekar, SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ,

Kapadnis BP, Simpson LL, Dessain SK. Neutralization of botulinum neurotoxin

by a human monoclonal antibody specific for the catalytic light chain. PLoS

ONE. 2008 Aug 20;3(8):e3023.

Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ, Simpson, LL, and

Dessain, SD. Hybridoma populations enriched for affinity-matured human IgGs

yield high-affinity antibodies specific for botulinum neurotoxins. J

Immunol Methods. 2008 Apr 20;333(1-2):156-166. Epub 2008 Feb 20.

Adekar, SP, Al-Saleem, FH, Elias, MD, Simpson, LL, and Dessain, SD. A

natural human IgM antibody that neutralizes botulinum neurotoxin in vivo.

Hybridoma (Larchmt). Hybridoma (Larchmt). 2008 Apr;27(2):65-9.

Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ, Simpson, LL, and

Dessain, SD. A human monoclonal antibody that binds serotype A botulinum

neurotoxin. Hybridoma (Larchmt). Hybridoma (Larchmt). 2008 Feb;27(1):11-7.

Dessain SK, Adekar SP, Stevens JB, Carpenter KA, Skorski ML, Barnoski BL,

Goldsby RA, Weinberg RA. High efficiency creation of human monoclonal

antibody-producing hybridomas. (2004) J Immunol Methods 291(1-2):109-22.

Nonexperimental articles. (Articles in Books)

Dessain, SK, Adekar, SP, and Berry, JD. Exploring the native human

antibody repertoire to create anti-viral therapeutics. Curr Top Microbiol

Immunol. 2008;317:155-83. Review.

Oral Presentation

Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ, Simpson, LL and

Dessain, SK. Human monoclonal antibodies neutralizing botulinum neurotoxin

in vivo. 46th ICAAC, San Francisco, CA, 2006.

Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ, Simpson, LL and

Dessain, SK. Use of a novel hetero-hybridoma method to clone potent, high

affinity human antibodies specific for botulinum neurotoxins. Second Annual

Jefferson Postdoctoral Research Symposium, Thomas Jefferson University,

Philadelphia, PA, June, 2007.

Adekar, SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ,

Kapadnis BP, Simpson LL, Dessain SK. Neutralization of botulinum neurotoxin

by a human monoclonal antibody specific for the catalytic light chain.

Second Annual Botulinum Research Symposium, University of Massachusetts

Dartmouth, Aug 21-22, 2008.

Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Shupp H, Root, MJ,

Kapadnis BP, Simpson, LL and Dessain, SK. Human Monoclonal Antibodies

Cloned By A Novel Hybridoma Method Neutralize Botulinum Neurotoxin in vivo.

Interagency Botulism Research Coordinating Committee Meeting,

Philadelphia, Sep 14-18,2008.

Adekar, SP, Jones, RM, Elias, MD, Tsuyoshi T, Al-Saleem, FH, Root, MJ,

Kapadnis BP, Simpson, LL and Dessain, SK. Creation of hybridoma populations

from post-germinal center B-cells and their use to clone human antibodies

specific for botulinum neurotoxins. The14th International Conference on

Human Antibodies and Hybridomas, New York, 12-14 November 2008.

Poster Presentations

Adekar, SP, Bulakh, PM, Melinkeri, RR. Role of Nitric Oxide in Renal

Diseases. Association of Clinical Biochemistry of India Annual Meeting,

Nagpur, India, 2001.

Dessain, SK, Adekar, SP, Rybinski, KA, Barnoski, B, Goldsby, RA, Weinberg,

RA. Neutralization of botulinum neurotoxin with a single human antibody

cloned using a new human antibody cloning method. Bio2005, Philadelphia,

PA, June 19-22, 2005.

Adekar, SP, Elias, MD, Rybinski, KA, Al-Saleem, FH, Maksymowych, AB,

Simpson,LL and Dessain, SK. Human Antibodies that Bind Botulinum

Neurotoxin A. International Conference on Basic and Therapeutic Aspects of

Botulinum and Tetanus Toxins, Denver, CO, June 23-25, 2005.

Dessain, SK, Rybinski, KE, Adekar, SP, Rauova, L, Sachias, BS, McKenzie,

SE, Reilly, MP. A Human Antibody, Cloned from a Patient with Heparin-

Induced Thrombocytopenia, that Binds Heparin/Platelet Factor 4 Complexes.

33rd Annual Philadelphia Workshop on Hemostasis, Thrombosis and

Atherosclerosis. Thomas Jefferson University, Philadelphia, PA, November

18, 2005.

Dessain, SK, Rybinski, KA, Adekar, SP, Raouva, L, Sachias, B, McKenzie, SE,

Reilly, MP. A human antibody, cloned from a patient with heparin-induced

thrombocytopenia, that binds heparin/platelet factor 4 complexes. American

Society of Hematology 47th Annual Meeting, Atlanta, GA, December 10-13,

2005.

Dessain, SK, Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ,

Simpson, LL. Use of a novel hetero-hybridoma method to clone potent, high

affinity human antibodies specific for botulinum neurotoxins. The13th

International Conference on Human Antibodies & Hybridomas, Milan, Italy, 29-

31 October 2007.

Dessain, SK, Adekar, SP, Klyubin, I, Macy, SD, Rowan, MJ, Solomon, A,

O'Nuallain, B. Human Immunoglobulin Heavy Chains Have Novel Fibril-binding

And Anti-amyloidogenic Activity. International Conference on Alzheimer's

Disease, Vienna, Austria, July 11-16, 2009.

US Patent Applications

Adekar, SP, Simpson LL and Dessain, SK. Monoclonal antibodies that

neutralize botulinum neurotoxin.

Patent serial no: 11/455,507

Adekar, SP, Dessain SK. A method of creating libraries of hybrid cells that

express useful antibodies.

Docket no: 37075-0225-P1-US (223452)

Adekar, SP, Dessain SK. Fusion partner cell line for preparation of hybrid

cells expressing human antibodies.

Docket no: 37075-0226-P1-US (225641)

O'Nuallain, B, Dessain SK, Adekar, SP. Use of Immunoglobulin heavy and

light chains

or fragments thereof to bind to aggregated amyloidogenic proteins.

Docket no: 747-0117



Contact this candidate